Invesco Ltd. : Form 8.3 - Informa PLC FORM 8.3

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
25
Invesco Ltd. : Form 8.3 - Informa PLC

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code")

1.         KEY INFORMATION

(a) Full name of discloser:   Invesco Ltd.
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):   The naming of nominee or vehicle companies is insufficient.  For a trust, the trustee(s), settlor and beneficiaries must be named.    
(c) Name of offeror/offeree in relation to whose relevant securities this form relates:   Use a separate form for each offeror/offeree     Informa Plc.
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:    
(e) Date position held/dealing undertaken:   For an opening position disclosure, state the latest practicable date prior to the disclosure   23 May 2018
(f)  In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?   If it is a cash offer or possible cash offer, state "N/A"   Yes: UBM Plc.  

2.         POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

  1. Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
Class of relevant security:     0.1p Ordinary GB00BMJ6DW54 ADR US45672B3050
      Interests Short positions
  Number   % Number   %
(1) Relevant securities owned and/or controlled:   44,097,270   5.35%      
(2) Cash-settled derivatives:                
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:              
    TOTAL:   44,097,270   5.35%      

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

  1. Rights to subscribe for new securities (including directors' and other employee options)
Class of relevant security in relation to which subscription right exists:    
Details, including nature of the rights concerned and relevant percentages:    

3.         DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1©, copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

  1. Purchases and sales
Class of relevant security   Purchase/sale     Number of securities   Price per unit
ADR (1:2)   Sale   5,280   20.54 USD
Ordinary   Purchase   49,520   7.70 GBP

 (b)       Cash-settled derivative transactions

Class of relevant security   Product description e.g. CFD   Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short  position   Number of reference securities   Price per unit
                   

(c)        Stock-settled derivative transactions (including options)

(i)         Writing, selling, purchasing or varying

Class of relevant security   Product description e.g. call option   Writing, purchasing, selling, varying etc.   Number of securities to which option relates   Exercise price per unit   Type e.g. American, European etc.   Expiry date   Option money paid/ received per unit
                             

(ii)        Exercise

Class of relevant security   Product description e.g. call option   Exercising/ exercised against   Number of securities   Exercise price per unit
                   

(d)        Other dealings (including subscribing for new securities)

Class of relevant security   Nature of dealing e.g. subscription, conversion   Details   Price per unit (if applicable)
               

4.         OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.  If there are no such agreements, arrangements or understandings, state "none"
None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i)  the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state "none"
  None  

(c)        Attachments

Is a Supplemental Form 8 (Open Positions) attached?   NO
Date of disclosure:   24 May 2018
Contact name:   Philippa Holmes
Telephone number:   01491 417 447

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .  The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 34

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 35

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 24

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 26

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 37

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 35

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading

Top 5 Most Recently Viewed Articles

Man Group PLC Highlights Its Strategic Disclosures on Tritax REIT

Updated Category News Views 148

Strategic Position Disclosure by Man Group PLC Man Group PLC is actively sharing its significant interests in the securities market, particularly focusing on its involvement with Tritax Big Box REIT plc. As a key player in the investment landscape, this disclosure marks an important step for the company regarding its strategic holdings. Key Information Pertaining to the...

Continue Reading
TalentLMS and Epignosis Lead the Way in GDPR Compliance

Updated Category News Views 720

TalentLMS and Epignosis Set the Standard for GDPR Compliance TalentLMS, along with its parent company Epignosis, has continuously led the way in providing a fully compliant Learning Management System (LMS) with regards to the General Data Protection Regulation (GDPR). Recent developments affirm that TalentLMS remains the only LMS globally to uphold its commitment to this...

Continue Reading
Zillow and Esusu Forge New Path to Boost Renters' Credit Scores

Updated Category News Views 283

Building Credit for Renters with Zillow and Esusu The recent collaboration between Zillow and Esusu marks a significant step towards empowering renters across the country to build their credit. This partnership allows any renter to report their on-time rent payments, significantly enhancing their credit profiles, for just $20 a year. How the Partnership Works Starting...

Continue Reading
iCrowdNewswire Leverages DeepL for Enhanced Global Communication

Updated Category News Views 121

iCrowdNewswire Enhances Multilingual Capabilities iCrowdNewswire, a prominent international press release distribution company, has embarked on a transformative journey to improve its multilingual services through the introduction of the DeepL API. The integration of DeepL's cutting-edge language AI technology has significantly boosted iCrowdNewswire’s ability to...

Continue Reading
Celebrating Excellence: Top Surgeons Recognized in Endocrine Care

Updated Category News Views 82

Exceptional Recognition for Leading Surgeons in Endocrine Surgery Dr. Jim Norman and Dr. Gary Clayman Acknowledged as Premier Specialists The Hospital for Endocrine Surgery is proud to announce that two of its distinguished surgeons, Dr. Jim Norman and Dr. Gary Clayman, have been honored in the prestigious Castle Connolly Top Doctors list for 2025. This remarkable...

Continue Reading